Protalix BioTherapeutics, Inc. has completed a private stock placement
Protalix BioTherapeutics, Inc. has raised funds to refinance the company for further development.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received the approval of the US Food and Drug Administration, for the treatment of Gaucher disease.
Oaklins’ team in Israel advised Protalix BioTherapeutics, Inc. and acted as a member in the distributors’ consortium.
Talk to the deal team
Related deals
Groupe Nature acquires Winco
Groupe Nature has signed an agreement with Nicolas Watine, founder and CEO of Winco, to acquire his stake in the comany. It specializes in the distribution of health and cosmetic products in parapharmacies affiliated to supermarket chains. This acquisition strengthens Groupe Nature’s position as a multi-channel specialist in the distribution of organic health products.
Learn moreCamelia pharmacy chain has been acquired by Medigate Management UAB
CGP Management UAB has sold the Camelia pharmacy chain (UAB Nemuno vaistinė and subsidiaries) to Medigate Management UAB.
Learn moreShield Therapeutics has raised funds
Shield Therapeutics Plc has completed a placing, subscription and open offer. The primary use of the funds is to launch Accrufer® in the USA.
Learn more